For research use only. Not for therapeutic Use.
ITF 3756 is a potent and selective HDAC6 inhibitor. ITF 3756 reduces in vitro the expression of PD-L1 on human monocytes and on CD8 T cells, and shows anti-tumor activity[1].
| Catalog Number | I029649 |
| CAS Number | 2247608-27-9 |
| Synonyms | N-hydroxy-4-[(5-thiophen-2-yltetrazol-1-yl)methyl]benzamide |
| Molecular Formula | C13H11N5O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C13H11N5O2S/c19-13(15-20)10-5-3-9(4-6-10)8-18-12(14-16-17-18)11-2-1-7-21-11/h1-7,20H,8H2,(H,15,19) |
| InChIKey | UFUGFWWXDWPEQE-UHFFFAOYSA-N |
| SMILES | C1=CSC(=C1)C2=NN=NN2CC3=CC=C(C=C3)C(=O)NO |
| Reference | [1]. Gianluca Fossati, et al. Abstract 1358: The selective HDAC6 inhibitor ITF3756 stimulates an antitumor immune response and leads to tumor regression in combination with anti CTLA-4 antibody in a colon carcinoma murine model. Cancer Res (2022) 82 (12_Supplement): 1358. |
